[HTML][HTML] The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez, B Ballester, A Morell, I Roger… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
[HTML][HTML] The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez… - Respiratory …, 2018 - respiratory-research.biomedcentral …
Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal fibrotic disorder,
with no curative therapies. The signal transducer and activator of transcription 3 (STAT3) …
with no curative therapies. The signal transducer and activator of transcription 3 (STAT3) …
The JAK2 pathway is activated in idiopathic pulmonary fibrosis.
J Milara, G Hernandez, B Ballester… - Respiratory …, 2018 - search.ebscohost.com
Abstract < bold> Background: </bold> Idiopathic pulmonary fibrosis (IPF) is the
most rapidly progressive and fatal fibrotic disorder, with no curative therapies. The signal …
most rapidly progressive and fatal fibrotic disorder, with no curative therapies. The signal …
[HTML][HTML] The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez, B Ballester, A Morell… - Respiratory …, 2018 - ncbi.nlm.nih.gov
Background Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J MILARA, G Hernandez, B Ballester, A Morell, I Roger… - 2018 - repositori.uji.es
Background: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
[引用][C] The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez, B Ballester, A Morell… - Respiratory …, 2018 - cir.nii.ac.jp
The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J MILARA, G Hernandez, B Ballester, A Morell, I Roger… - 2018 - lareferencia.info
Background: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
The Jak2 Pathway Is Activated In Idiopathic Pulmonary Fibrosis
J Milara, G Hernandez, B Ballester, A Morell… - … Research, 2018, Vol …, 2018 - diposit.ub.edu
Background: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez, B Ballester… - Respiratory …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
[PDF][PDF] The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez, B Ballester, A Morell, I Roger… - 2018 - academia.edu
Background: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …